MECP2 and myeloid sarcoma: In this study, we develop a procedure to identify potential MeCP2 binding sites over false positives, and we apply this procedure to selected gene-sets derived from several genetic studies on neuropathologies: autism11, attention deficit hyperactivity disorder (ADHD)12, major depressive disorder (MDD)13, bipolar disorder (BIP)14 ,anorexia15, epilepsy16, Alzheimer’s disease (AD)17, Parkinson’s Disease (PD)18, Huntington’s disease (HTT)19, amyotrophic lateral sclerosis (ALS)20, multiple sclerosis (MS)21, and schizophrenia (SCZ)22.